Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 11/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 9/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15022986 | 0.82 | MAPK10 (0.57) | GRM5KCNH2TTRPDE10AMAPK10 | |
| SCHEMBL15022990 | 0.78 | MAPK10 (0.58) | GRM5KCNH2TTRPDE10AMAPK10 | |
| SCHEMBL15022071 | 0.77 | MAPK9 (0.56) | GRM5KCNH2TTRPDE10AMAPK10 | |
| SCHEMBL3270389 | 0.77 | PDE10A (0.67) | PDE10ACYP1A2 | |
| SCHEMBL30123632 | 0.77 | PDE10A (0.67) | PDE10ACYP1A2 | |
| SCHEMBL15043369 | 0.74 | GRM5 (0.42) | GRM5KCNH2TTRPDE10AMAPK10 | |
| SCHEMBL15022969 | 0.73 | MAPT (0.34) | GRM5MAPK10MAPK9MAPK8 | |
| SCHEMBL11253060 | 0.73 | NOTUM (0.43) | MAPK10MAPK9CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12884286 | 0.73 | GRM5 (0.65) | GRM5KCNH2TTRNPC1CYP1A2 | |
| SCHEMBL15022094 | 0.73 | HDAC8 (0.44) | GRM5MAPK10MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158031-A1 | ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF | SU ZHOU JING HONG BIOTECH CO., LTD. (CN) | 2013-06-20 | — | — | US | disclosed |
| US-20130158031-A1 | ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF | SU ZHOU JING HONG BIOTECH CO., LTD. (CN) | 2013-06-20 | — | — | US | disclosed |
| US-20130158031-A1 | ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF | SU ZHOU JING HONG BIOTECH CO., LTD. (CN) | 2013-06-20 | — | — | US | disclosed |
| CN-103159738-A | Mixed aromatic compound of alkynyl bridging and application thereof | SHANGHAI HONGBO ZHIYUAN MEDICAL TECHNOLOGY CO LTD | 2013-06-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158031-A1 | ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF | CHRNA10, ATXN10, SCN10A | GRM5 472/4885KCNH2 548/4885TTR 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.